These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
390 related items for PubMed ID: 7525363
1. Different tumours, transduced with different cytokine genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions. Stoppacciaro A, Forni G, Colombo MP. Folia Biol (Praha); 1994; 40(1-2):89-99. PubMed ID: 7525363 [Abstract] [Full Text] [Related]
2. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice. Provinciali M, Argentati K, Tibaldi A. Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579 [Abstract] [Full Text] [Related]
3. Role of neutrophils and lymphocytes in inhibition of a mouse mammary adenocarcinoma engineered to release IL-2, IL-4, IL-7, IL-10, IFN-alpha, IFN-gamma, and TNF-alpha. Musiani P, Allione A, Modica A, Lollini PL, Giovarelli M, Cavallo F, Belardelli F, Forni G, Modesti A. Lab Invest; 1996 Jan; 74(1):146-57. PubMed ID: 8569177 [Abstract] [Full Text] [Related]
4. Antitumor effect of interleukin (IL)-12 in the absence of endogenous IFN-gamma: a role for intrinsic tumor immunogenicity and IL-15. Gri G, Chiodoni C, Gallo E, Stoppacciaro A, Liew FY, Colombo MP. Cancer Res; 2002 Aug 01; 62(15):4390-7. PubMed ID: 12154045 [Abstract] [Full Text] [Related]
5. Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma. Stoppacciaro A, Melani C, Parenza M, Mastracchio A, Bassi C, Baroni C, Parmiani G, Colombo MP. J Exp Med; 1993 Jul 01; 178(1):151-61. PubMed ID: 7686211 [Abstract] [Full Text] [Related]
6. Role of neutrophils and CD4+ T lymphocytes in the primary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. Cavallo F, Giovarelli M, Gulino A, Vacca A, Stoppacciaro A, Modesti A, Forni G. J Immunol; 1992 Dec 01; 149(11):3627-35. PubMed ID: 1358974 [Abstract] [Full Text] [Related]
13. Nature and potential of the reactive response to mouse mammary adenocarcinoma cells engineered with interleukin-2, interleukin-4 or interferon-gamma genes. Musiani P, Modesti A, Brunetti M, Modica A, Vitullo P, Gulino A, Bosco MC, Colombo MP, Nanni P, Cavallo F. Nat Immun; 1994 Dec 01; 13(2-3):93-101. PubMed ID: 8173240 [Abstract] [Full Text] [Related]
15. Involvement of immune responses in the eradication of IL-1 alpha gene-transduced tumour cells: mechanisms of tumour rejection and immunotherapeutical implications. Apte RN, Douvdevani A, Zoller M, White RM, Dvorkin T, Shimoni N, Huleihel M, Fima E, Hacham M, Voronov E. Folia Biol (Praha); 1994 Dec 01; 40(1-2):1-18. PubMed ID: 7958060 [Abstract] [Full Text] [Related]
16. Immunizing and curative potential of replicating and nonreplicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and gamma-interferon gene or admixed with conventional adjuvants. Allione A, Consalvo M, Nanni P, Lollini PL, Cavallo F, Giovarelli M, Forni M, Gulino A, Colombo MP, Dellabona P. Cancer Res; 1994 Dec 01; 54(23):6022-6. PubMed ID: 7954438 [Abstract] [Full Text] [Related]